Sites
- cancer.gov
- cancer.org
- drugbank.ca
- drugs.com
- mayoclinic.org
- medicalnewstoday.com
- medscape.com
- news-medical.net
- nih.gov
- sciencedaily.com
- webmd.com
Tags
- A
- ABL
- Acalabrutinib
- Accelerated
- Accelerated approval
- Active ingredient
- Active site
- Acute lymphoblastic leukemia
- Adenosine triphosphate
- Afatinib
- Aflibercept
- Aggressive fibromatosis
- Akt/PKB signaling pathway
- Alectinib
- Alemtuzumab
- Alzheimer's disease
- American Society of Health-System Pharmacists
- Amine
- Amitriptyline
- Amoxapine
- Amphiregulin
- Amyloid beta
- An
- Anaplastic lymphoma kinase
- Anemia
- Apoptosis
- Aripiprazole
- Atezolizumab
- Atherosclerosis
- Atlanto-axial joint
- Attenuated vaccine
- Avelumab
- Axitinib
- Baricitinib
- Basic fibroblast growth factor
- BBC News
- Bcl-2
- Bcr-abl tyrosine kinase
- Benzamide
- Bevacizumab
- Billion
- Binding site
- Bioavailability
- Biological half-life
- Biological target
- Blinatumomab
- Blood–brain barrier
- Bone marrow suppression
- Brain-derived neurotrophic factor
- Break
- Breast cancer
- Breast Cancer Research
- Brentuximab vedotin
- Brian Druker
- Brigatinib
- Buclizine
- Buspirone
- Cabozantinib
- Cancer
- Cancer Cell
- Cancer center
- Cancer immunotherapy
- Cancer research
- Cancer Research Foundation
- Cardiac muscle
- CAS Registry Number
- Catalysis
- CD117
- CD135
- CD20
- CD3
- CD33
- CD52
- Ceritinib
- Cetirizine
- Cetuximab
- ChEBI
- ChEMBL
- Chemical formula
- Chemotherapy
- Chloramphenicol
- Chronic myelogenous leukemia
- Ciclosporin
- Cinnarizine
- Ciprofloxacin
- Clarithromycin
- Clinical Trials
- Clozapine
- C-Met
- Cobimetinib
- Colony-stimulating factor
- Counterion
- Crizotinib
- C-terminus
- CTGF
- Cyclizine
- Cyclodextrin
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
- CYP3A4
- Cytochrome P450
- Dacomitinib
- DailyMed
- Damon Runyon Cancer Research Foundation
- Dana–Farber Cancer Institute
- Daratumumab
- Dasatinib
- Deep Forest
- Dehydroepiandrosterone
- Dehydroepiandrosterone sulfate
- Dexamethasone
- Diabetes mellitus
- Docking
- Document
- DOI
- DrugBank
- Drug class
- Drug design
- Drug metabolism
- Drug nomenclature
- Durvalumab
- Edema
- Enfortumab vedotin
- Enzyme inhibitor
- Ephrin B2
- Epidermal growth factor
- Epidermal growth factor receptor
- Epiregulin
- Epithelial cell adhesion molecule
- ErbB
- ERBB3
- ERBB4
- Erdafitinib
- Erlotinib
- Erythropoietin
- Etoperidone
- European Chemicals Agency
- European Patent Office
- Everolimus
- Excretion
- Exotoxin
- Federal level
- Fedratinib
- FGF1
- Fibroblast growth factor
- Fibroblast growth factor 23
- Fibroblast growth factor receptor
- Fibroblast growth factor receptor 1
- Fibroblast growth factor receptor 2
- Filgotinib
- Flibanserin
- Fluphenazine
- Food and Drug Administration
- Forestry
- Fusion protein
- Gamma secretase
- Gastrointestinal bleeding
- Gastrointestinal stromal tumor
- Gefitinib
- GFRA1
- Glial cell line-derived neurotrophic factor
- Grapefruit juice
- Growth factor receptor
- Half-life
- Hammersmith Hospital
- HDL
- Heart failure
- Heparin-binding EGF-like growth factor
- Hepatocyte growth factor
- HER2/neu
- High-throughput screening
- Hydroxyzine
- Ibrutinib
- Icotinib
- IGF-1 LR3
- ImmunoGen
- Immunotherapy
- Inactivated vaccine
- Incyte
- Inotuzumab ozogamicin
- Insulin
- Insulin-like growth factor 1
- Insulin-like growth factor 1 receptor
- Insulin receptor
- Interferon
- Interleukin
- Interleukin 2
- International Chemical Identifier
- International Standard Book Number
- In vitro
- Ipilimumab
- Isatuximab
- Ischemia
- Isozyme
- Itraconazole
- JAK-STAT signaling pathway
- Janus kinase
- Jmol
- KEGG
- Ketoconazole
- Kidney
- KIT
- Kraš
- Lapatinib
- Larotrectinib
- Lead compound
- Lenvatinib
- Leukemia
- Levothyroxine
- Liver
- Liver disease
- Low-affinity nerve growth factor receptor
- Lurasidone
- Lymphatic system
- Lymphoma
- Malignancy
- Masitinib
- Mast cell
- Mastocytosis
- Mayo Clinic
- Mecasermin
- Mecasermin rinfabate
- Mechanism of action
- Meclizine
- MedlinePlus
- Memorial Sloan Kettering Cancer Center
- Mesylate
- Metabolite
- Metástasis
- Metoprolol
- Midkine
- Midostaurin
- Miglitol
- Mirtazapine
- Mitogen-activated protein kinase kinase
- Mogamulizumab
- Molar mass
- Molecular targeted therapy
- Molecule
- Momelotinib
- Monoclonal antibody therapy
- Mouse
- MTOR inhibitors
- Myelodysplastic syndrome
- Myeloid
- Myeloproliferative neoplasm
- Need
- Needs
- Nefazodone
- Neratinib
- Nerve growth factor
- Neurofibroma
- Neurofibromatosis type I
- Neuroprotection
- Neuroprotective therapies
- Neurotrophin-3
- Neutropenia
- New York Times
- Nilotinib
- Nintedanib
- Nivolumab
- No
- Novartis
- N-terminus
- Obinutuzumab
- Ofatumumab
- Olanzapine
- Oncogene
- Oncology
- Opipramol
- Opposition proceeding
- Oral administration
- Oregon Health & Science University
- Osimertinib
- Pacritinib
- Palbociclib
- Paracetamol
- Pazopanib
- PDE
- Pembrolizumab
- Personalized Medicine
- Pertuzumab
- Pharmaceutical drug
- Pharmaceutical formulation
- Pharmacokinetics
- Pharmacology
- Phenyl group
- Philadelphia chromosome
- Phosphate
- Phosphodiesterase inhibitor
- Phosphorylation
- Pimozide
- PIPES
- Pirenzepine
- Placental growth factor
- Plasma protein binding
- Pleiotrophin
- PMC
- Polymorphism
- Ponatinib
- Precision medicine
- Pregnancy
- Pregnancy category
- Prescription drug
- Prochlorperazine
- Protein Data Bank
- Protein kinase inhibitor
- Protein pigeon homolog
- PubChem
- Puberty
- PubMed
- Pulmonary fibrosis
- Pulmonary hypertension
- Pyrimidine
- Quizartinib
- R13
- R7
- Ranibizumab
- Ranolazine
- Receptor modulator
- Receptor tyrosine kinase
- Regorafenib
- Regulation of therapeutic goods
- Reoccurrence
- Research foundation
- Ribociclib
- Rifampicin
- Ritonavir
- Rituximab
- Route of administration
- Ruxolitinib
- Salt
- Sega Wow
- Selegiline
- Selumetinib
- Semaxanib
- Side Effects
- Signal transduction
- Sildenafil
- Simvastatin
- Skinny Label
- Small molecule inhibitor
- Smallpox
- Sorafenib
- SRC
- Standard for the Uniform Scheduling of Medicines and Poisons
- Stem cell factor
- St John's wort
- Subdural hematoma
- Substrate
- Sunitinib
- Supreme Court of India
- Systemic scleroderma
- Tadalafil
- Targeted therapy
- Teprotumumab
- Testosterone
- Therapy
- The washington post
- Thiothixene
- Thrombocytopenia
- Thrombopoietin
- Time
- Toxoid
- Trametinib
- Trastuzumab
- Trazodone
- Treatment of cancer
- Tricyclic
- Trimetazidine
- Trofinetide
- Tropomyosin receptor kinase A
- Tucatinib
- Tyrosine
- Tyrosine kinase
- Tyrosine-kinase inhibitor
- United States Patent and Trademark Office
- University of Milano-Bicocca
- University of North Carolina at Chapel Hill
- USA Today
- Vandetanib
- Vardenafil
- Vascular endothelial growth factor
- Vascular endothelial growth factor A
- VEGF receptor
- Venetoclax
- Vilazodone
- Vismodegib
- Vortioxetine
- Warfarin
- Water retention
- Wayback Machine
- WHO Model List of Essential Medicines
- Wnt signaling pathway
- World Health Organization
- World Trade Organization
- X-ray crystallography
- Ziprasidone